Cue Biopharma (CUE) Cash from Financing Activities (2017 - 2025)

Cue Biopharma has reported Cash from Financing Activities for 9 years, with the latest figure at $9.5 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 1118.45% year-over-year to $9.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.3 million (up 156.67% YoY) and the FY2025 annual result came in at $26.3 million, up 156.67% from the prior year.
• Cash from Financing Activities grew to $9.5 million in Q4 2025 per CUE's latest filing, from $1000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $27.4 million in Q4 2022 and troughed at -$1.0 million in Q2 2024.
• A 5-year average of $6.1 million and a median of $3.5 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 51088.89% in 2023, then plunged 147.6% in 2024.
• Over 5 years, Cash from Financing Activities stood at $7.4 million in 2021, then soared by 271.2% to $27.4 million in 2022, then tumbled by 82.55% to $4.8 million in 2023, then plunged by 119.49% to -$932000.0 in 2024, then soared by 1118.45% to $9.5 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $9.5 million, $1000.0, and $17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.